# Creams and lotions tried to prevent chemotherapy hair loss

Source: https://onco.cc/technologies/hair-topical-prevention-agents/  
OnCo record `hair-topical-prevention-agents` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Several drugs have been put on the scalp to stop chemotherapy hair loss before it starts: minoxidil lotion, vitamin D analogues, and others. The trials were done and they did not work. Scalp cooling remains the only method cleared by a regulator to prevent it.

## Summary

This record exists so that the question is answered rather than left open, because it is the first thing people ask and the answer is unwelcome. A meta-analysis of interventions to prevent chemotherapy-induced alopecia (Shin et al., International Journal of Cancer 2015) pooled 8 randomised and 9 controlled trials covering 1,098 participants. Scalp cooling significantly reduced the risk of alopecia, with a relative risk of 0.38 (95 per cent confidence interval 0.32 to 0.45); topical 2 per cent minoxidil and the other interventions tested did not significantly reduce it.

The individual failures are worth naming. Topical minoxidil was tested for prevention in a randomised trial of 48 women receiving doxorubicin (Rodriguez et al., Annals of Oncology 1994): 88 per cent and 92 per cent of patients in the two arms had severe alopecia, a difference that was not significant. Topical calcipotriol, a vitamin D analogue that protects rodent hair follicles, was tested in a randomised controlled trial in women receiving CMF chemotherapy (Bleiker et al., British Journal of Dermatology 2005) and had no detectable effect on any measure: the proportion with minimal hair loss, shed rates, plucked telogen and fractured hair counts, the shape of shed and plucked hair, regrowth or hair density. An earlier phase 1 study of topical calcitriol found that all 14 patients developed moderate alopecia and that eight developed a toxic rash where the drug had been applied.

Newer topical calcitriol formulations reached phase 1 in taxane-treated patients and were reported as safe, with alopecia of less than 50 per cent in 8 of 23 patients at week 7, but no phase 2 or phase 3 trial of it has been registered. AS101, a tellurium compound, prevented alopecia as an incidental finding in a 44-patient trial designed to test marrow protection, and no trial of it for hair has been registered since. The practical conclusion for a reader is that minoxidil is a treatment for hair that is slow to return, not a shield for hair you still have, and that the only prevention with a regulator behind it is cooling.

## Fields

- Kind: Technology
- Status: negative
- Last checked: 2026-10-02
- Tags: complementary; supportive-care; hair-loss; evidence:no-benefit
- Principle: Each of these aimed to make the follicle temporarily less vulnerable, by pushing it out of the dividing phase or by local cell-cycle arrest, so that a drug circulating in the blood would do it less damage. Scalp cooling takes the other route, reducing how much of the drug arrives.
- Strengths: The question has actually been tested, repeatedly, rather than left to opinion; Knowing what does not work stops money and hope going to it
- Limitations: Individual trials were small; Negative results for one dose and schedule do not rule out another; Newer agents stalled after phase 1 rather than failing outright, which is a different kind of nothing

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Chemotherapy-induced_alopecia
- Shin et al., efficacy of interventions for prevention of chemotherapy-induced alopecia: systematic review and meta-analysis (International Journal of Cancer 2015): https://doi.org/10.1002/ijc.29115
- Bleiker et al., atrophic telogen effluvium from cytotoxic drugs and a randomised controlled trial of topical calcipotriol (British Journal of Dermatology 2005): https://doi.org/10.1111/j.1365-2133.2005.06608.x
- Lacouture et al., prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines (Annals of Oncology 2021): https://doi.org/10.1016/j.annonc.2020.11.005

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [Scalp cooling (cold caps: DigniCap, Paxman)](https://onco.cc/technologies/scalp-cooling/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Anagen effluvium (chemotherapy hair loss)](https://onco.cc/terms/hair-anagen-effluvium/)
- bottlenecks: [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/hair-topical-prevention-agents.json